A new initiative has been launched with the goal of expediting the development and availability of messenger RNA (mRNA) vaccine candidates for human avian influenza (H5N1).
The World Health Organisation (WHO), alongside the Medicines Patent Pool (MPP), made this known in a joint statement published by WHO on Monday, stating that the H5N1 is for manufacturers in low and middle-income countries (LMICs).
It said Sinergium Biotech, an Argentinian manufacturer, will spearhead this…
Read the full article here